Marlio Charles Mosseri Increases Stake in Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) reported that major shareholder Marlio Charles Mosseri has acquired a significant number of shares in the company. On February 7, Mosseri purchased 240,000 shares at an average price of $5.00 each, amounting to a total investment of $1,200,000. Following this transaction, he now holds 2,884,121 shares, which are valued at around $14,420,605. This purchase reflects a 9.08% increase in his ownership stake in Nuvectis Pharma. The details of this transaction were disclosed in a filing with the Securities and Exchange Commission (SEC), which can be accessed on their official website.

In addition to this recent acquisition, Mosseri made another purchase on December 13, when he bought 17,000 shares of Nuvectis Pharma at an average price of $4.70 per share, totaling $79,900. This indicates Mosseri's growing confidence in the company.

Nuvectis Pharma Stock Performance

The trading performance of Nuvectis Pharma has seen some fluctuations. As of Wednesday, the stock opened at $6.29. Over the past year, the shares have reached a low of $4.44 and a high of $12.10. The current 50-day moving average price stands at $5.63, while the 200-day moving average is at $6.34. Nuvectis Pharma's market capitalization is approximately $121.52 million, with a price-to-earnings ratio of -5.42 and a beta factor of 0.22, indicating lower volatility compared to the market.

Institutional Activity

Recent movements from institutional investors reflect a positive interest in Nuvectis Pharma. Several hedge funds have made changes to their holdings in the company. For instance, Nations Financial Group Inc. IA ADV entered a new position valued at approximately $63,000 in the third quarter. Similarly, Oppenheimer & Co. Inc. also acquired a new position worth about $135,000 in the fourth quarter. Furthermore, GSA Capital Partners LLP increased its position by 3.7%, resulting in a total ownership of 50,129 shares valued at $315,000 after buying more shares during the third quarter. Forbes J M & Co. LLP raised its holdings by 21.9% during the fourth quarter, owning 59,000 shares valued at around $319,000. Lastly, Iridian Asset Management LLC CT acquired a new position worth approximately $348,000. Overall, institutional investors hold 96.77% of the company's stock, showcasing strong confidence in Nuvectis Pharma's future prospects.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing precision medicines aimed at addressing significant unmet medical needs in oncology. The company's lead candidate, NXP800, is a novel small molecule currently in Phase 1b clinical trials to treat patients suffering from platinum-resistant, ARID1a-mutated ovarian carcinoma.

Conclusion

The increased purchasing of shares by Marlio Charles Mosseri suggests confidence in Nuvectis Pharma's growth potential. Additionally, the engagement of institutional investors indicates a broader market interest and support for the company's mission in oncology.

Nuvectis, Pharma, shares